
TRAX Stock Forecast & Price Target
TRAX Analyst Ratings
Bulls say
First Tracks is supported by a clinically de-risked lead asset in ANB033, which delivered statistically significant and clinically meaningful benefit in Phase Ib celiac disease and is advancing with Cohort 2 topline data on track for 1Q27 and a late-stage celiac program expected in 2027. The bull case is strengthened by multiple near-term catalysts across the pipeline—ongoing EoE enrollment with data in 3Q27, a planned vitiligo Phase II start in 1H27, and additional indication disclosure in 1H27—while external IL-15/CD122 and BDCA2 readthroughs have validated the company’s mechanism and broadened its commercial potential. Financially, the outlook is further supported by sum-of-the-parts models that ascribe meaningful NPV to ANB033 across celiac, EoE, and vitiligo, plus anticipated YE27 net cash, with recent capital raise dilution already reflected in valuations.
Bears say
First Tracks is exposed to substantial clinical and mechanism risk, as ANB033 and ANB101 could fail in celiac disease, EoE, vitiligo, or beyond Phase 1, while competitor setbacks could still cast doubt on CD122 and BDCA2 validation. The company also faces commercialization risk because rosnilimab may not find a partner, and the excerpts highlight a crowded autoimmune landscape where differentiated efficacy and safety will be hard to prove. As a clinical-stage biotech with no stated cash-generating base, it could burn more cash than expected and be forced into financing that dilutes shareholders and pressures returns.
This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRAX Analyst Forecast & Price Prediction
Start investing in TRAX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About First Tracks Biotherapeutics Inc (TRAX) Forecast
TRAX Analyst Forecast & Price Prediction
Start investing in TRAX
Order type
Buy in
Order amount
Est. shares
0 shares